Chinese firm Sinovac Biotech told Bangladesh in September last year that it didn’t have money to pay for the vaccine trials and its request for funding to CEPI had been declined.

Trials for Chinese Covid-19 vaccine Sinovac were halted in Bangladesh.

Last year due to meddling by India.

China’s state media has claimed in a report on Tuesday.

Accusing New Delhi of torpedoing Beijing’s efforts to push its vaccine in Dhaka.

A nationalist tabloid run by the Communist Party of China, is Beijing’s response.

To a report in the that outlined how Bangladesh rescinded.

Its decision to allow Covid vaccine trials last October after a last-minute.

Demand by Chinese firm Sinovac Biotech that Dhaka co-fund the trials.

“But the clinical trials delayed until October due to the Indian government.

Allegedly meddling in the two sides’ cooperation during the period”.

the report – one of the many that China’s tightly-controlled media has published to target vaccines made by India and western companies – said.

to Sinovac Biotech’s 22 September letter to the Bangladesh letter, the trials scheduled.

In August had to pushed back due to delay in approvals from Dhaka.

The company had, according to this letter seen by, claimed that it had “reallocated our funds for the trial (in Bangladesh).

To trials in other countries, since, at the time, we were uncertain about the ultimate approval of the trial in Bangladesh.”

According to Sinovac Biotech’s 22 September letter to the Bangladesh letter.

The trials scheduled in August had to pushed back due to delay in approvals from Dhaka.

The company had, according to this letter seen by , claimed that it had “reallocated our funds for the trial (in Bangladesh).

To trials in other countries, since, at the time, we were uncertain.

About the ultimate approval of the trial in Bangladesh.”

Sinovac Biotech also claimed that it had requested the Coalition for Epidemic Preparedness Innovations (CEPI).

n organisation set up to accelerate the development of vaccines against emerging infectious diseases.

To fund the trials in Bangladesh but this application rejected